Aspirin for Your Heart? Decongestants? Here Are 5 Popular Medications that You Should Avoid

Key Takeaways

• Aspirin offers no net benefit for primary prevention
• Phenylephrine shows no efficacy beyond placebo
• Colace ineffective as sole stool softener
• Diphenhydramine poses sedation risks to seniors
• Codeine cough syrup lacks proven cough relief

Pulse Analysis

Recent cardiovascular studies have reshaped the role of low‑dose aspirin in people without prior heart attacks or strokes. Large meta‑analyses reveal that gastrointestinal and intracranial bleeding outweigh modest reductions in myocardial infarction risk, prompting major societies to downgrade aspirin from a routine primary‑prevention tool to a case‑by‑case decision. This shift forces clinicians to revisit long‑standing prescribing habits and encourages patients to discuss individualized risk assessments with their physicians. The change also reduces unnecessary drug exposure, potentially lowering national healthcare expenditures linked to bleeding complications. Moreover, the updated guidance aligns with precision‑medicine trends that prioritize individualized benefit‑risk calculations.

The over‑the‑counter decongestant phenylephrine, a staple in many cold remedies, has been declared ineffective by an FDA advisory panel after multiple trials failed to demonstrate superiority over placebo. Consumers often assume equivalence with pseudoephedrine, yet the active compound produces minimal vasoconstriction at standard doses. This regulatory clarification pushes pharmacists and physicians to recommend alternative nasal sprays or non‑pharmacologic measures for congestion relief. By eliminating an ineffective ingredient, patients can avoid unnecessary medication costs and potential side‑effects such as elevated blood pressure. Insurance formularies are beginning to exclude phenylephrine, further nudging clinicians toward evidence‑based alternatives.

Other common agents—docusate sodium (Colace), diphenhydramine, and codeine‑based cough syrups—are also under scrutiny. Randomized studies show docusate offers no advantage over placebo for softening stools, while diphenhydramine increases sedation and falls risk in older adults. Likewise, a 2014 Cochrane review found codeine provides no meaningful cough suppression compared with inert syrup. Deprescribing these low‑value drugs can streamline medication regimens, improve safety for vulnerable populations, and generate modest savings for insurers and patients alike. Pharmacy‑wide medication reviews have proven effective in identifying these candidates for removal.